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Objectives. To assess the feasibility of treating musculoskeletal pain in the lower back and/or lower extremities in persons with
Parkinson’s disease (PD) with cranial electrotherapy stimulation (CES). Design. Randomized, controlled, double-blind trial.
Setting. Veterans Aﬀairs Medical Center, Community. Participants. Nineteen persons with PD and pain in the lower back and/or
lower extremities. Thirteen provided daily pain rating data. Intervention. Of the thirteen participants who provided daily pain
data, 6 were randomly provided with active CES devices and 7 with sham devices to use at home 40 minutes per day for six weeks.
They recorded their pain ratings on a 0-to-10 scale immediately before and after each session. Main Outcome Measure. Average
daily change in pain intensity. Results. Persons receiving active CES had, on average, a 1.14-point decrease in pain compared with
a 0.23-point decrease for those receiving sham CES (Wilcoxon Z =− 2.20, P = .028). Conclusion. Use of CES at home by persons
with PD is feasible and may be somewhat helpful in decreasing pain. A larger study is needed to determine the characteristics of
persons who may experience meaningful pain reduction with CES. Guidelines for future studies are provided.
1.Introduction
Reports of the prevalence of pain and other sensory
s y m p t o m si np e r s o n sw i t hP Dh a v er a n g e df r o m3 4 %t o
85% [1–8]. Several authors have reported that pain may
be the ﬁrst presenting symptom of PD; however, it is
only in retrospect that the relationship to PD becomes
clear [3, 4, 6, 9–14]. Once antiparkinsonian medication is
instituted, pain may ﬂuctuate with “on” and “oﬀ” periods
and with ﬂuctuations in dystonia [7, 11]. In some cases,
antiparkinsonian medication may initiate the pain or make
it worse [11]. Pain may be chronic, become more prevalent,
occur in a wider area of the body, and/or become more severe
as PD progresses [7, 15, 16].
Various classiﬁcation schemes have been suggested in
reference to the etiology of sensory symptoms in PD. Based
on category schemes previously developed by Goetz et al.
[5] and Quinn et al. [11], Ford [7] proposed a modiﬁed 5-
category scheme for classifying pain associated with PD: (a)
musculoskeletal pain (pain due to rigidity, rheumatologic
disease, or skeletal deformity), (b) neuropathic-radicular
pain (pain due to root lesion, focal or peripheral neuropa-
thy), (c) dystonic pain (related to abnormal tonicity and
timing of dose of medication), (d) central pain (lesion or
abnormality of function within the central nervous system
and related to timing and dose of medication), and (e)
akathisia (oﬀ period or drug-induced). Goetz et al. [5]f o u n d
pain such as muscle cramps or tightness to be the most
common (74% of patients with pain) followed by dystonias,
usually in the feet (28%). Radicular, neuritic, joint, and
generalized pains were less common (2% to 14%).2 Parkinson’s Disease
Occurrence and severity of pain may be related to
other symptoms of PD such as tremor; rigidity; akinesia;
dyskinesia, alterations in stance, gait, or mobility; postural
deformities; radiculopathy; sciatica; myelopathy; and dysto-
nia [7, 17]. Pain is also often associated with psychological
conditions such as depression, anxiety, and sleep disorders
[6, 7, 15, 17–20].
Recommended treatment for pain in patients with PD
depends on the source of the problem [7]. If the pain
is related to antiparkinsonian medication, the dose of the
medication may need to be regulated upward or downward
o rat r i a lw i t had i ﬀerent antiparkinsonian medication may
be indicated [7, 17, 21]. If the source of the pain is muscu-
loskeletal in nature, physical therapy [7], exercise [7], oral
appliances [22], nonsteroidal anti-inﬂammatory drugs [7],
analgesics [7], botulism toxin [7, 23], and arthroscopic or
orthopedic surgery [7, 24] may be indicated [17]. For other
etiologies,tricyclicagents,gabapentin,opiates,andclozapine
may be helpful [7, 9, 19, 22]. Honey et al. [25] found that
PD-related pain was signiﬁcantly reduced with unilateral
pallidotomy. Loher et al. [26] found that unilateral pallidal
deep brain stimulation relieved sensory symptoms best on
the contralateral side but had a lesser eﬀect on the ipsilateral
side. Bilateral deep brain stimulation also was found to
relieve sensory symptoms [26]. Concurrent psychological
symptoms such as depression, anxiety, and sleeplessness may
require treatment speciﬁc to the problem (e.g., antidepres-
sants) in addition to other measures taken to relieve pain.
Cranial Electrotherapy Stimulation (CES). CES is a non-
invasive technique used to treat a variety of conditions
involving the application of a small amount of electric
current through the head via ear-clip electrodes. The anal-
gesic action of subperception CES has been demonstrated
in various antinociception models [27–29]. Extracellular
recording techniques indicated that CES modiﬁes noxious
evoked responses in pain-processing regions of the brains
of rats [30, 31]. In humans, the mechanism of action of
CES is not fully understood; however, it has been shown
to “normalize” neurotransmitter homeostasis [32], stimulate
the hypothalamic-pituitary axis by increasing IGF-1 produc-
tion [33], bring neurotransmitters in stressed participants
back to normal levels of homeostasis [34], and increase β-
endorphins in patients with chronic back pain [35].
A review of the use of CES in the management of chronic
pain [36] concluded that CES has been found to be eﬀective
in decreasing spinal pain [37], headache pain [38–40], dental
pain [41, 42], and pain-related muscle spasms [43–45], as
well as controlling a variety of conditions that are often
associated with pain—anxiety, depression, insomnia, and
generalized stress [46]. CES has been found to have very
f e wn e g a t i v es i d ee ﬀects. There have been reports of slight
irritation at the electrode sites [39], burns at the electrode
site [47], slight dizziness [43], headache [48], giddiness
[48], and tooth pain [48]. In a recent study, Tan et al.
found CES to be eﬀective in relieving musculoskeletal and
neuropathic pain in persons with spinal cord injury (SCI)
[49]. Not only was there a signiﬁcant diﬀerence in the
decrease in pain from before to after daily sessions between
those who received active CES versus those who received
sham CES, but also there was a signiﬁcant change in pain
interferencewithseveralquality-of-lifedomainsfrompre-to
postintervention.
To our knowledge there have been no studies published
regarding the use of CES for pain management in the PD
population. Therefore, we conducted a small initial study
to determine (a) the feasibility of using CES at home to
relievechronicmusculoskeletalpaininthelowerbackand/or
lower extremities in the PD population, regardless of pain
etiology, (b) whether a larger study is warranted, and (c)
how to best design any future study of CES in the PD
population. Musculoskeletal pain in the lower back and/or
lower extremities was selected for the study because it is
common among persons with PD [5], thus increasing the
likelihood of recruiting a suﬃcient number of participants.
Limiting the study to only lower body pain ensured a more
homogeneous sample and lower body pain is more disabling
because it aﬀects mobility.
2. Methods
From July 2005 through June 2006 a convenience sample
was recruited through the Parkinson’s Disease Research,
Education, and Clinical Center at the Michael E. DeBakey
Veterans Aﬀairs Medical Center (MEDVAMC), the newslet-
ter of the Houston Area Parkinson Society, and word of
mouth. This feasibility study was designed to include up
to 20 participants. This sample size was selected based on
the availability of resources to support a part-time study
coordinator and other project costs. Inclusion criteria were
(a) diagnosis of PD (diagnosis code of 332.0) conﬁrmed
by a movement disorder specialist, (b) at least one chronic
musculoskeletal pain in the lower back and/or lower extrem-
ity (not necessarily PD-related pain) that began at least six
months prior to study entry, (c) average pain intensity rated
at the time of recruitment as at least 5 on a scale of 0 (no
pain) to 10 (pain as bad as you can imagine), and (d) speak
and understand English. Exclusion criteria were (a) current
substanceabuseproblem,(b)currentlyundertreatmentfora
seriouspsychologicalorpsychiatricdisorderthatcouldaﬀect
ability to participate in the study, (c) moderate or severe
cognitive impairment (score <21 on the Telephone Interview
for Cognitive Status (TICS) [50]), (d) implanted electrical
device (e.g., cardiac pacemaker, deﬁbrillator, or deep brain
stimulator), and (e) pregnancy.
Participants signed an informed consent form approved
by Baylor College of Medicine and the MEDVAMC. The
participants completed questionnaires and were trained in
the use of the CES device and Daily Pain Rating Sheet. They
were randomized to receive either an active or a sham CES
device for use at home during the study.
The CES equipment used was the Alpha-Stim SCS
(Supplier: Electromedical Products International, Inc, 2201
Garrett Morris Parkway, Mineral Wells, TX 76067-9034
USA), which is a prescription medical technology that is
Federal Drug Administration approved for the management
of pain, anxiety, depression, and insomnia. The device is
illustrated in Figure 1. Half of the devices provided activeParkinson’s Disease 3
Figure 1: Cranial electrostimulation therapy (CES) device.
CES and the other half had no electric current ﬂowing.
Active devices provided subsensory stimulation of 100
microamperes. Active and sham devices were identical in
appearance and were identiﬁed only with a serial number.
Participantsandthestudycoordinatorwereblindedtogroup
assignment and the code sheet indicating which devices were
active and which were sham was kept by another person
who was not in contact with the participants. Participants
in both the active and sham groups were taught how to
use the device, provided with printed instruction sheets, and
instructed to use the device 40 minutes daily for six weeks.
They were provided with ear clip electrode pads, conducting
solution with which to wet the pads, and 9-volt batteries.
A summary of the measures is provided in Table 1.S t a n -
dardized scales included the TICS [50], the Hoehn and Yahr
(HY) Staging of PD Scale [51], and the Uniﬁed Parkinson’s
Disease Rating Scale (UPDRS) [52]. The UPDRS motor scale
was administered by a PD specialist. Demographic and PD
data and information on pain and side eﬀects were provided
by the participants. The participants were instructed to
provide daily pain ratings on a 0-to-10 scale immediately
before and immediately after the end of each 40-minute CES
session during the 42-day trial.
For each participant, average pre- and postsession pain
ratings were calculated across the number of daily sessions
completed. The diﬀerence between the average pre- and
postsession ratings yielded an average mean change score.
Diﬀerences in pain ratings between the active and sham
groups were assessed with nonparametric Mann-Whitney
U tests. Within groups, nonparametric Wilcoxon Signed
Rank tests were performed to determine whether there was
signiﬁcant pre- to postsession change. The average percent
of change from before to after sessions was calculated and
Mann-Whitney U tests were performed to assess diﬀerences
between groups.
3. Results
Nineteen participants were recruited and randomized to the
active or sham condition. Nine (47.4%) participants had
low back pain, two (10.5%) had lower extremity pain, seven
(36.8%) had both low back and lower extremity pain, and
the speciﬁc location of the “study pain” was missing for one
(5.3%) participant. The mean number of days a month with
pain was 26.3 ± 6.2 and the mean number of hours a day
with pain was 7.6 ± 4.2. Characteristics of the sample can
be seen in the column labeled “Overall” in Table 2.T h e r e
were no signiﬁcant demographic diﬀerences between the
initial active (n = 9) and sham (n = 10) groups. There
also was no signiﬁcant diﬀerence between the groups in
average pain intensity in the past week at the time of the
screening telephone call or at the time of the initial visit to
the MEDVAMC.
Thirteen (68%) participants provided at least some daily
pain data and the remainder of this report concerns data
from these 13 participants. Half of the six who did not
provide daily data had received active CES devices and
half had received sham devices. Reasons for missing daily
pain ratings were as follows: Active—never started using the
device for an unknown reason (n = 1), frustrated, and
concernedthathewasnotusingitcorrectly,sostoppedusing
it and did not return the pain rating sheet (n = 1), and based
on weekly telephone contact data another participant used
the device but did not return the daily pain rating sheet for
an unknown reason (n = 1); and Sham—never started using
t h ed e v i c eb e c a u s eh em o v e d( n = 1), did not understand
how to complete the daily pain rating sheet, and only put
checkmarks indicating that she used the device each day
but did not rate pain intensity before and after each session
(n = 1) and completed but then lost the rating sheet (n = 1).
3.1. Daily Pain Ratings. Of the 13 recruits who returned at
least some daily pain ratings, 6 were in the active group and 7
in the sham group. There was no signiﬁcant diﬀerence in the
demographic and PD data between those who did and did
not return daily pain rating data or between the active and
sham groups who provided daily data (Table 2). On average,
the participants with data provided ratings for 31 (74%) of
the 42 sessions planned for in the study protocol.
Displayed in Figure 2 are the average daily pain ratings
for the active and sham groups. For the active group, the
average daily rating was 4.89 ± 1.22 before and 3.75 ± 2.04
after the sessions yielding an average decrease of 1.14 ± 1.21
points(Wilcoxon Z =− 2.20,P = .028).Fortheshamgroup,
the average rating was 3.82 ± 1.76 before and 3.59 ± 1.75
after yielding an average decrease of 0.23 ± 0.33 (Wilcoxon
Z =− 1.36,P = .173).AscanbeseeninFigure 2,withineach
group, average daily change was quite consistent across time.
The average diﬀerence between the groups in change scores
(1.14 versus 0.23) was signiﬁcant (Mann-Whitney U = 7.00,
P = .045), indicating that pain reduction in the active group
was greater than that in the sham group.
Three (50%) of the six active CES participants with
daily ratings had an average daily decrease in pain intensity
of at least one point (3.41, 1.35, and 1.14). None of the4 Parkinson’s Disease
Table 1: Summary of measures.
Measure Purpose Administration
schedule
Demographic and PD Data
Describe participants and their PD (age,
gender, race/ethnicity, marital status,
l e v e lo fe d u c a t i o n ,a g ea tw h i c hP Dw a s
diagnosed and time since PD diagnosis).
Preintervention
Telephone Interview for
Cognitive Status
Exclude persons with moderate or severe
cognitive impairment (scores <21) Preintervention
Hoehn and Yahr Staging of
Parkinson’s Disease Scale Classify stage of PD Preintervention
Uniﬁed Parkinson’s Disease
Rating Scale
Measure mentation, behavior and mood,
activities of daily living, motor function,
and complications of therapy
Preintervention
I n f o r m a t i o no nP a i n
Describe pain location on body drawings;
days per month and hours per day with
pain. Rate average pain on a 0-to-10 scale
scale with end points “no pain” and “pain
as bad as you can imagine”
Preintervention
Daily Pain Rating Sheet
Measure current pain intensity
immediately before and immediately after
each daily session of active or sham CES
(0-to-10 scale with end points “no pain”
and “pain as bad as you can imagine”).
Daily during
6-week
intervention
(self-administered)
CES: Cranial Electrotherapy Stimulation; PD: Parkinson’s disease.
sham group had a decrease of at least one point. The
decreases in the active group represented 90, 29, and
21 percent, respectively, of their average before-session
ratings. Decreases between 10 and 20 percent are considered
minimally clinically important, decreases ≥30 percent are
moderately clinically important, and decreases ≥50 percent
are considered substantial [53]. Only one person in the sham
group had a decrease of greater than 20 percent and he had a
very low average before-session pain rating of 0.49. However,
a Mann-Whitney U test revealed no signiﬁcant diﬀerence
between the groups on percentage change (U = 11.00,
P = .153).
Side eﬀects were minimal: Active—pulsing, tickling, or
tingling sensations on ears (n = 3), tender ears (n = 1),
and pins-and-needles sensation near the bladder (n = 1);
and Sham—drowsiness (n = 1), warm ears (n = 1), and
headache after one session (n = 1). Some participants had
diﬃculty manipulating the ear clips and/or replacing the
small electrode pads. No serious study-related adverse events
occurred during this study.
4. Discussion
This small initial study examined the feasibility of using CES
for chronic musculoskeletal pain in persons with PD. The
participants were able to use the devices at home, sometimes
with the help of a family member. Side-eﬀects were mild
and did not cause withdrawals. The results suggest that there
may be some beneﬁt from CES for some individuals. The
consistency of the daily change scores across the 6-week trial
suggests that the results were not due to a placebo eﬀect.
Theprimarylimitationsofthestudyarethesmallsample
size and a large number of participants without daily pain
ratings (32% of 19 recruits). The two participants who never
startedusingthedevicewerebothmaleswhoratedtheirpain
asa5onthe0-to-10scaleatintake(theminimumpainrating
thatmetthecriteria).However,manyotherparticipants who
didusethedevicealsohadaninitialpainratingof5,suggest-
ingthatitmaynothavebeenlessintensepainthatinﬂuenced
thenonuseofthedevice.Clearly,bettertrainingontheuseof
thedailypainratingsheetisneededtoincreasethelikelihood
of usable data. In addition, perhaps the daily rating sheet
data should be obtained and recorded by project staﬀ during
weekly telephone contacts to avoid possible loss of data.
The small sample limits our ability to generalize the
ﬁndings to other persons with PD who have musculoskeletal
pain in the lower-body. Larger studies are needed to assess
the eﬀect of CES on pain in persons with PD to extend the
ﬁndings of the present study. Furthermore, based on the
data from the active group, it is clear that some participants
had a better response to the treatment than others. Future
studies should be large enough to assess diﬀerences between
responders and nonresponders to identify any characteristics
that may be predictive of successful pain management
through the use of CES.
In spite of meeting the criterion at the time of recruit-
ment that pain intensity was rated as at least a 5 on a scale
of 0 to 10, some participants had an average before-sessionParkinson’s Disease 5
Table 2: Characteristics of the sample.
Characteristic Overall
N = 19
Active with
Daily Data
n = 6
Sham with
Daily Data
n = 7
Demographic Information
Age at study entry (mean ± SD) 72.4 ± 8.0 74.7 ± 7.8 74.4 ± 8.3
Gender—n (%)
Male 15 (78.9) 4 (66.7) 6 (85.7)
Female 4 (21.1) 2 (33.3) 1 (14.3)
Race/Ethnicity—n (%)
Caucasian 15 (78.9) 5 (83.3) 6 (85.7)
African American 1 (5.3) 0 (0.0) 0 (0.0)
Hispanic 3 (15.8) 1 (16.7) 1 (14.3)
Telephone Interview for Cognitive Status (TICS)
(mean ± SD) 32.8 ± 3.1 32.5 ± 3.9 34.1 ± 2.0
Parkinson’s Disease Information
Age when diagnosed with PD (mean ± SD) 62.6 ± 11.1 59.5 ± 12.4 69.2 ± 9.4
Time since diagnosis at study entry (mean ± SD) 10.6 ± 8.6 15.2 ± 12.9 5.2 ± 2.4
Hoehn and Yahr stage of PD—n (%)
1.5 Unilateral disease with axial involvement 1 (5.3) 0 (0.0) 1 (14.3)
2.0 Bilateral disease without impairment of balance 6 (31.6) 0 (0.0) 2 (28.6)
2.5 Mild bilateral disease with recovery on pull test 5 (26.3) 4 (66.7) 1 (14.3)
3.0 Mild to moderate bilateral disease, some postural
instability, physically independent 6 (31.6) 1 (16.7) 3 (42.9)
4.0 Severe disability, still able to walk or stand
unassisted 1 (5.3) 1(16.7) 0 (0.0)
Uniﬁed Parkinson’s Disease Rating Scale (UPDRS)
(mean ± SD)
Mentation, Behavior, and Mood (maximum score=16) 2.3 ± 1.9 1.8 ± 1.6 3.3 ± 1.9
Activities of Daily Living (maximum score = 52) 14.3 ± 5.1 14.7 ± 5.2 14.4 ± 5.0
Motor Exam (maximum score = 108) 28.5 ± 12.7 27.3 ± 11.2 26.4 ± 12.6
UPDRS Total Score (maximum score = 176) 47.5 ± 18.1 46.2 ± 15.5 46.1 ± 17.0
Complications of Therapy (maximum score = 23) 2.5 ± 2.0 2.3 ± 1.4 2.0 ± 1.3
PD: Parkinson’s disease; SD: standard deviation.
pain intensity rating below 5 during the 6-week trial. The
factthattheactivegrouphadapproximatelyonepointhigher
average before-session scores than the sham group, despite
random assignment to groups, may have had an eﬀect on
the results although average change in pain intensity was
not signiﬁcantly related to the average before-session pain
ratings (Spearman rho =− 0.15, P = .615). The percentage
changewasalsonotsigniﬁcantlyrelatedtothebefore-session
pain rating (Spearman rho = 0.11, P = .720). In future
studies, stratiﬁcation based on initial pain ratings before
randomizationmayimprovethesimilarityofthetwogroups.
In spite of randomization, the active group was, on
average, 10 years younger than the sham group at the time of
diagnosis ofPDand,time sincediagnosis was10yearslonger
for the active group at study entry, (Table 2). What eﬀect
these diﬀerences may have had on the results is unknown;
however, neither change in pain intensity nor percentage
of change in pain intensity was related to age at diagnosis
(change in pain: Spearman rho = 0.28, P = .364; percentage
change in pain: Spearman rho = 0.41, P = .162) or time
since diagnosis (change in pain: Spearman rho =− 0.36,
P = .231; percentage change in pain: Spearman rho =− 0.22,
P = .471). In future studies, stratiﬁcation on age at diagnosis
and time since diagnosis may be wise in order to better
equalize the groups.
Another apparent, but not signiﬁcant diﬀerence between
the groups was the UPDRS Mentation subscale (Table 2).
However, since the possible total score on the subscale
is 16 and the diﬀerence between the groups is only 1.5
points, this is not considered to be a meaningful clinical
diﬀerence. Scores between 1 and 4 are considered to indicate
mild conditions. Mentation was not signiﬁcantly related to
change in pain (Spearman rho =− .05, P = .878) or
percentagechangeinpain(Spearmanrho =− .33,P = .270).
Furthermore,thegroupshadverysimilarscoresontheTICS.
We did not do a manipulation check regarding how
successful the blinding of the participants was. Asking the
participants whether they believed they had an active or6 Parkinson’s Disease
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Figure 2: Average daily pain ratings before and after CES sessions
for active and sham groups.
sham device would have been instructive on this point.
Since the before to after session eﬀect of active CES on
pain remained relatively constant from week to week, it
may not be necessary to have such a long trial in future
studies. Persons initially assigned to sham CES should be
given the opportunity to subsequently try open-label active
CES.Theresultsoftheopen-labelphasecouldstrengthenthe
conclusions, if CES is eﬀective.
Additional suggestions for future studies are as follows:
(a) daily before-and-after session pain ratings should be
included in any assessment of the eﬀectiveness of CES to
relieve pain in persons with PD and the duration of pain
relief after the session, if any, should be assessed; (b) daily
treatments should be 60 minutes long in studies that use the
subsensory current level (i.e., 100μA) to better compensate
forthelowcurrent;(c)trialsareneededinwhichthestrength
of the electric current is set above subsensory levels to
determine if there is a “dose” response; (d) improvements
in the design of the ear clips to make it easier for persons
with poor hand muscle control would be helpful for PD and
other disability populations; (e) improvement in training
participants to use the device at home would be helpful, such
as provision of a DVD with instructions and demonstrations
to be used at home.
5. Conclusion
In spite of the limitations, the present study met the goals of
an initial study. Our ﬁndings suggest that using CES at home
is feasible in the PD population without serious unintended
eﬀects and there may be a decrease in pain for some persons.
Alargerstudyisneededtoextendourﬁndings,andthestudy
provided methodological guidance for future studies.
Abbreviations
ANOVA: Analysis of variance
CES: Cranial electrotherapy stimulation
HY: Hoehn and Yahr Staging of Parkinson’s
Disease Scale
MEDVAMC: Michael E. DeBakey Veterans Aﬀairs Medical
Center
PD: Parkinson’s disease
TICS: Telephone Interview for Cognitive Status
UPDRS: Uniﬁed Parkinson’s Disease Rating Scale.
Acknowledgments
The authors wish to thank Daniel Kirsch, Ph.D. of Elec-
tromedical Products International, Inc., Mineral Wells, TX,
for the generous provision of Alpha-Stim SCS units and
supplies (batteries, ear pads, and conducting solution) for
use in this study as well as his advice and consultation. They
also wish to thank Electromedical Products International,
Inc. for the unrestricted gift to the Department of Physical
Medicine and Rehabilitation at Baylor College of Medicine.
In addition, they are very grateful to Huma Qureshy,
PT, for volunteering to enter a substantial portion of the
data. Pamela Willson is now with College of Nursing,
P r a i r i eV i e wA & MU n i v e r s i t y ,H o u s t o n ,T e x a s .T h i ss t u d y
was supported, in part, by the Veterans Aﬀairs Rehabili-
tation Research and Development Service, the Michael E.
DeBakey Veterans Aﬀairs Medical Center, and through an
unrestricted gift to the Department of Physical Medicine
and Rehabilitation at Baylor College of Medicine as well
as the electrotherapy devices and associated supplies by
Electromedical Products International, Inc., Mineral Wells,
TX.
References
[ 1 ]F .H .L e w y ,Die Lehre vom Tonus und der Bewegung: Zugleich
Systematische Untersuchungen Zur Klinik, Physiologie, Patholo-
gie und Pathogenese der Paralysis Agitans, Springer, Berlin,
Germany, 1923.
[2] J. Sigwald and J. Solignac, “Manifestations douloureuses de
la maladie de Parkinson et paresthesies provoquees par les
neuroleptiques,” Semaine Des Hopitaux Paris, vol. 41, pp.
2222–2225, 1960.
[3] S. R. Snider, S. Fahn, W. P. Isgreen, and L. J. Cote, “Primary
sensory symptoms in parkinsonism,” Neurology, vol. 26, no. 5,
pp. 423–429, 1976.
[4] W. C. Koller, “Sensory symptoms in Parkinson’s disease,”
Neurology, vol. 34, no. 7, pp. 957–959, 1984.Parkinson’s Disease 7
[ 5 ]C .G .G o e t z ,C .M .T a n n e r ,M .L e v y ,R .S .W i l s o n ,a n dD .
C. Garron, “Pain in Parkinson’s disease,” Movement Disorders,
vol. 1, no. 1, pp. 45–49, 1986.
[6] Z. Marinkovi´ c, V. Kosti´ c, N. Covikovi´ c-Sterni´ c, and S.
Marinkovi´ c, “Pain in patients with Parkinson disease,” Srpski
Arhiv Za Celokupno Lekarstvo, vol. 118, pp. 463–466, 1990.
[7] B. Ford, “Pain in Parkinson’s disease,” Clinical Neuroscience,
vol. 5, no. 2, pp. 63–72, 1998.
[8] M. Schenkman, T. M. Cutson, C. W. Zhu, and K. Whetten-
Goldstein, “A longitudinal evaluation of patients’ perceptions
of Parkinson’s disease,” Gerontologist, vol. 42, no. 6, pp. 790–
798, 2002.
[9] R. Sandyk, “Back pain as an early symptom of Parkinson’s
disease,” South African Medical Journal,v o l .6 1 ,n o .1 ,p .3 ,
1982.
[10] G. D. Schott, “Pain in Parkinson’s disease,” Pain,v o l .2 2 ,n o .4 ,
pp. 407–411, 1985.
[11] N. P. Quinn, W. C. Koller, A. E. Lang, and C. D. Marsden,
“Painful Parkinson’s disease,” Lancet, vol. 1, no. 8494, pp.
1366–1369, 1986.
[12] D. Riley, A. E. Lang, R. D. Blair, A. Birnbaum, and B.
Reid, “Frozen shoulder and other shoulder disturbances in
Parkinson’s disease,” Journal of Neurology, Neurosurgery, and
Psychiatry, vol. 52, no. 1, pp. 63–66, 1989.
[13] B. Scott, A. Borgman, H. Engler, B. Johnels, and S. M. Aquilo-
nius, “Gender diﬀerences in Parkinson’s disease symptom
proﬁle,” Acta Neurologica Scandinavica, vol. 102, no. 1, pp. 37–
43, 2000.
[14] S. Ito, M. Asahina, M. Asahina, T. Oki, and T. Hattori, “Severe
chronic pain with allodynia in Parkinson’s disease: a case
report,” Rinsho Shinkeigaku, vol. 41, no. 2-3, pp. 147–149,
2001.
[15] A. B. Shang and S. A. King, “Parkinson’s disease, depression,
and chronic pain,” Hospital and Community Psychiatry, vol.
42, no. 11, pp. 1162–1163, 1991.
[16] K. H. Karlsen, E. Tandberg, D. ˚ Arsland, and J. P. Larsen,
“HealthrelatedqualityoflifeinParkinson’sdisease:aprospec-
tive longitudinal study,” J o u r n a lo fN e u r o l o g y ,N e u r o s u r g e r y ,
and Psychiatry, vol. 69, no. 5, pp. 584–589, 2000.
[17] S. Waseem and K. Gwinn-Hardy, “Pain in Parkinson’s disease:
common yet seldom recognized symptom is treatable,” Post-
graduate Medicine, vol. 110, no. 6, pp. 33–34, 39–40, 46, 2001.
[18] C. G. Goetz, R. S. Wilson, C. M. Tanner, and D. C. Garron,
“Relationships among pain, depression, and sleep alterations
in Parkinson’s disease,” Advances in Neurology, vol. 45, pp.
345–347, 1986.
[19] W. M. Stein and S. Read, “Chronic pain in the setting
of Parkinson’s disease and depression,” J o u r n a lo fP a i na n d
Symptom Management, vol. 14, no. 4, pp. 255–258, 1997.
[20] M. Caap-Ahlgren and O. Dehlin, “Insomnia and depressive
symptoms in patients with Parkinson’s disease: relationship
to health-related quality of life. An interview study of patients
living at home,” Archives of Gerontology and Geriatrics, vol. 32,
no. 1, pp. 23–33, 2001.
[21] R. Sandyk, C. R. Bamford, and R. P. Iacono, “Pain and sensory
symptoms in Parkinson’s disease,” International Journal of
Neuroscience, vol. 39, pp. 15–25, 1988.
[22] S.Minagi,T.Matsunaga,T.Shibata,andT.Sato,“Anappliance
for management of TMJ pain as a complication of Parkinson’s
disease,” Cranio, vol. 16, no. 1, pp. 57–59, 1998.
[23] M. A. Grazko, K. B. Polo, and B. Jabbari, “Botulinum toxin A
for spasticity, muscle spasms, and rigidity,” Neurology, vol. 45,
no. 4, pp. 712–717, 1995.
[24] K. G. Vince, J. N. Insall, and C. E. Bannerman, “Total knee
arthroplasty in the patient withParkinson’s disease,” Journal of
Bone and Joint Surgery. British, vol. 71, no. 1, pp. 51–54, 1989.
[25] C. R. Honey, A. J. Stoessl, J. K. Tsui, M. Schulzer, and D. B.
Calne, “Unilateral pallidotomy for reduction of parkinsonian
pain,” J o u r n a lo fN e u r o s u r g e r y , vol. 91, no. 2, pp. 198–201,
1999.
[26] T. J. Loher, J.-M. Burgunder, S. Weber, R. Sommerhalder, and
J. K. Krauss, “Eﬀect of chronic pallidal deep brain stimulation
on oﬀ period dystonia and sensory symptoms in advanced
Parkinson’s disease,” Journal of Neurology, Neurosurgery, and
Psychiatry, vol. 73, no. 4, pp. 395–399, 2002.
[27] O. B. Wilson, R. F. Hamilton, R. L. Warner, et al., “The
inﬂuence of electrical variables on analgesia produced by low
currenttranscranialelectrostimulationofrats,”Anesthesiaand
Analgesia, vol. 68, no. 5, pp. 673–681, 1989.
[28] I. D. Capel, H. M. Dorrell, and E. P. Spencer, “The application
ofsub-perceptionelectricalstimulielicitsatemporallydistinct
response from restraint stress: I. Antinociceptive characteris-
tics,” Journal of Bioelectricity, vol. 9, no. 2, pp. 167–176, 1990.
[29] L. Gabis, B. Shklar, Y. K. Baruch, R. Raz, E. Gabis, and D.
Geva, “Pain reduction using transcranial electrostimulation:
a double-blind “active placebo” controlled trial,” Journal of
Rehabilitation Medicine, vol. 41, no. 4, pp. 256–261, 2009.
[30] J.-T. Qiao, M. Skolnick, and N. Dafny, “Dorsal raphe and
external electrical stimulation modulate noxious input to
single neurons in nucleus parafascicularis thalami,” Brain
Research Bulletin, vol. 21, no. 4, pp. 671–675, 1988.
[ 3 1 ]W . - Q .D o n g ,O .B .W i l s o n ,M .H .S k o l n i c k ,a n dN .D a f n y ,
“Hypothalamic, dorsal raphe and external electrical stim-
ulation modulate noxious evoked responses of habenula
neurons,” Neuroscience, vol. 48, no. 4, pp. 933–940, 1992.
[32] R. S. Pozos, L. F. Strack, R. K. White, and A. W. Richardson,
“Electrosleep versus electroconvulsive therapy,” in Neuroelec-
tric Research, D. V. Reynolds and A. E. Sjoberg, Eds., pp. 221–
225, Charles Thomas, Springﬁeld, Ill, USA, 1971.
[33] R. B. Smith and C. A. Ryser, “The use of cranial electrotherapy
stimulation (CES) in anti-aging medicine: great things we
learn when research goes wrong,” in Proceedings of the Inter-
national Oxidative Medicine Association Meeting, Westminster,
Colo, USA, March 2000.
[34] M. S. Gold, A. L. Pottash, H. Sternbach, J. Barbaban, and
W. Asunitto, “Anti-withdrawal eﬀect of alpha methyl dopa
a n dc r a n i a le l e c t r o t h e r a p y , ”i nProceedings of the Society
for Neuroscience Meeting, Minneapolis, Minn, USA, October
1982.
[35] L. Gabis, B. Shklar, and D. Geva, “Immediate inﬂuence
of transcranial electrostimulation on pain and β-endorphin
blood levels: an active placebo-controlled study,” American
Journal of Physical Medicine and Rehabilitation, vol. 82, no. 2,
pp. 81–85, 2003.
[36] D .L.KirschandR.B.Smith,“Theuseofcranialelectrotherapy
stimulation in the management of chronic pain: a review,”
NeuroRehabilitation, vol. 14, no. 2, pp. 85–94, 2000.
[37] A. D. Kulkarni and R. B. Smith, “The use of microcurrent
electrical therapy and cranial electrotherapy stimulation in
pain control,” Clinical Practice of Alternative Medicine, vol. 2,
pp. 99–102, 2001.
[38] P. Brotman, “Low-intensity transcranial electrostimulation
improves the eﬃcacy of thermal biofeedback and quiet-
ing reﬂex training in the treatment of classical migraine
headache,” American Journal of Electromedicine, vol. 6, pp.
120–123, 1989.8 Parkinson’s Disease
[39] S. Solomon, A. Elkind, F. Freitag, et al., “Safety and eﬀec-
tiveness of cranial electrotherapy in the treatment of tension
headache,” Headache, vol. 29, no. 7, pp. 445–450, 1989.
[40] T. J. Romano, “The usefulness of cranial electrotherapy in
the treatment of headache in ﬁbromyalgia patients,” American
Journal of Pain Management, vol. 3, pp. 15–19, 1993.
[41] M. S. Clark, L. M. Silverstone, J. Lindenmuth, et al., “An
evaluation of the clinical analgesia/anesthesia eﬃcacy on acute
pain using the high frequency neural modulator in various
dental settings,” Oral Surgery, Oral Medicine, Oral Pathology,
vol. 63, no. 4, pp. 501–505, 1987.
[42] R. Hochman, “Neurotransmitter modulator (TENS) for con-
trol of dental operative pain,” T h eJ o u r n a lo ft h eA m e r i c a n
Dental Association, vol. 116, no. 2, pp. 208–212, 1988.
[43] S. Forster, B. S. Post, and J. G. Benton, “Preliminary obser-
vations on electrosleep,” Archives of Physical Medicine and
Rehabilitation, vol. 44, pp. 481–489, 1963.
[44] F. Magora, A. Beller, L. Aladjemoﬀ, A. Magora, and J.
Tannenbaum, “Observations on electrically induced sleep in
man,” British Journal of Anaesthesia, vol. 37, no. 7, pp. 480–
491, 1965.
[45] D. L. Kirsch, The Science Behind Cranial Electrotherapy
Stimulation, Medical Scope, Edmonton, Canada, 2nd edition,
2002.
[46] D. L. Kirsch and F. N. Lerner, “Electromedicine: the other side
of physiology,” in Innovations in Pain Management: A Practical
Guide for Clinicians, R. S. Weiner, Ed., St. Lucie Press, Boca
Raton, Fla, USA, 1998.
[47] A. G. Marshall and C. E. Izard, “Cerebral electrotherapeutic
treatment of depressions,” Journal of Consulting and Clinical
Psychology, vol. 42, no. 1, pp. 93–97, 1974.
[48] K. Singh, “Sleep inducing devices a clinical trial with a Russian
machine,” International Journal of Neuropsychiatry, vol. 3, no.
4, pp. 311–318, 1967.
[49] G. Tan, D. H. Rintala, J. I. Thornby, J. Yang, W. Wade, and C.
Vasilev, “Using cranial electrotherapy stimulation to treat pain
associated with spinal cord injury,” Journal of Rehabilitation
Research and Development, vol. 43, no. 4, pp. 461–474, 2006.
[50] J. Brandt, M. Spencer, and M. Folstein, “The telephone inter-
view for cognitive status,” Neuropsychiatry, Neuropsychology
and Behavioral Neurology, vol. 1, no. 2, pp. 111–117, 1988.
[51] M. M. Hoehn and M. D. Yahr, “Parkinsonism: onset, progres-
sion and mortality,” Neurology, vol. 17, no. 5, pp. 427–442,
1967.
[52] S.FahnandR.L.Elton,“TheuniﬁedParkinson’sdiseaserating
scale,” in Recent Developments in Parkinson’s Disease, S. Fahn,
C. D. Marsden, D. B. Calne, and M. Goldstein, Eds., vol. 2,
pp. 153–163, 293–304, MacMillan Healthcare Information,
Florham Park, NJ, USA, 1987.
[53] R.H.Dworkin,D.C.Turk,K.W.Wyrwich,etal.,“Interpreting
the clinical importance of treatment outcomes in chronic pain
clinical trials: IMMPACT recommendations,” Journal of Pain,
vol. 9, no. 2, pp. 105–121, 2008.